CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 109 enrolled
Drug / intervention
lithium carbonatedrug
Likely dose
lithium carbonate 450mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00790582
NCT00790582Phase 2Completed
CompareCT.gov

A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Forbes Norris MDA/ALS Research Center·interventional·Posted Nov 13, 2008·Updated Oct 30, 2020

In Brief

A Phase 2 clinical trial evaluating lithium carbonate for Amyotrophic Lateral Sclerosis. Completed, enrolled 109 participants across 10 sites.

Detailed Summary

This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsMuscular Dystrophy Association

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 13, 2008
Enrollment StartMay 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.6 years ago

Interventions

lithium carbonatedrug

The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.